Comparison between QR678 neo and platelet rich plasma for hair growth -A retrospective study

: Androgenetic alopecia is the most common cause of hair loss, affecting self-esteem and quality of life. While platelet-rich plasma has been a standard treatment, it yields inconsistent results due to patient variability. QR678 Neo, a biomimetic peptide-based treatment, offers a standardized alternative. This study aimed to compare the efficacy and safety profiles of QR678 Neo and platelet-rich plasma in treating androgenetic alopecia. Objectives included evaluating improvements in hair density, hair quality, patient satisfaction, and reduction in hair fall. : This retrospective study compared the efficacy of QR678 Neo and platelet-rich plasma in 70 AGA patients. The study evaluated hair density, quality, and patient satisfaction over 6 months. : QR678 Neo showed a 30% improvement in hair density versus 18% with platelet-rich plasma (p<0.01). Patients treated with QR678 Neo reported superior satisfaction (VAS score 9.2 vs. 7.8). : QR678 Neo outperformed PRP in all evaluated parameters, offering a consistent and effective alternative for Androgenetic alopecia treatment.